论文部分内容阅读
博士后张健在中山医科大学免疫学林学颜教授指导下，进行了“肿瘤细胞株KBV200多药耐药性与中性鞘糖脂表达及免疫逃逸机制的研究”。首次以抗mdr－rihazyTne（核酶）为工具，探讨其对人口腔表皮样癌细胞耐药株（KBV200）的作用，研究显示人口腔表皮样癌细胞株（KB）和KBV200的
Zhang Jian, a postdoctoral doctor, under the guidance of Prof. Lin Xueyan, Immunology of Sun Yat-Sen University of Medical Sciences, conducted a study on the multidrug resistance of tumor cell line KBV200 and the expression of neutral glycosphingolipids and immune escape mechanism. The first use of anti-mdr-rihazyTne (ribozyme) as a tool to explore its role in human oral epidermoid carcinoma resistant strain (KBV200), studies showed that human oral epidermoid carcinoma cell line (KB) and KBV200